Labcorp Holdings Inc. $LH Stock: MBL Wealth LLC Lowers Stake

MBL Wealth LLC lessened its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 17.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,341 shares of the medical research company’s stock after selling 4,016 shares during the quarter. MBL Wealth LLC’s holdings in Labcorp were worth $5,959,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Fifth Third Bancorp increased its stake in shares of Labcorp by 106.5% in the first quarter. Fifth Third Bancorp now owns 57,981 shares of the medical research company’s stock worth $15,470,000 after buying an additional 29,899 shares during the period. Public Employees Retirement System of Ohio bought a new stake in Labcorp during the 2nd quarter valued at $7,792,000. Tidal Investments LLC boosted its position in Labcorp by 12.4% during the 2nd quarter. Tidal Investments LLC now owns 30,559 shares of the medical research company’s stock valued at $8,557,000 after buying an additional 3,372 shares during the period. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Labcorp during the 2nd quarter valued at $168,222,000. Finally, Royal Bank of Canada boosted its position in Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock valued at $218,901,000 after buying an additional 133,549 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

LH opened at $330.48 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The stock has a market capitalization of $26.80 billion, a PE ratio of 18.51, a price-to-earnings-growth ratio of 1.85 and a beta of 0.87. The stock’s 50 day moving average price is $320.72 and its 200-day moving average price is $290.72. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $341.80.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, equities research analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s dividend payout ratio is 23.82%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LH shares. Mizuho set a $355.00 price target on shares of Labcorp in a report on Monday, August 10th. JPMorgan Chase & Co. upped their price objective on shares of Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday. Barclays increased their target price on shares of Labcorp from $320.00 to $330.00 and gave the stock an “equal weight” rating in a report on Friday, September 11th. Finally, Morgan Stanley raised their target price on Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $337.73.

Insiders Place Their Bets

In related news, CEO Adam H. Schechter sold 4,669 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the transaction, the chief executive officer owned 102,565 shares in the company, valued at $32,858,749.05. The trade was a 4.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kerrii B. Anderson sold 3,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. The trade was a 31.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,593 shares of company stock worth $2,733,295. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Company Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.